https://www.hmpgloballearningnetwork.com/site/gastro/news/resmetirom-reduces-portal-hypertension-risk-and-fibrosis-markers-mash-cirrhosis-2
Resmetirom Reduces Portal Hypertension Risk and Fibrosis Markers in MASH Cirrhosis at 2 Years
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis....
https://www.uchicagomedicine.org/forefront/gastrointestinal-articles/resmetirom-fda-approval
UChicago Medicine will begin offering resmetirom - UChicago Medicine
Resmetirom (Rezdiffra) is the first drug approved for metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as fatty liver disease.
uchicago medicinebeginofferingresmetirom
https://es.rezdiffra.com/
Rezdiffra® (resmetirom) para adultos que padecen MASH con cicatrización en el hígado sin cirrosis
Mar 11, 2026 - Obtén información sobre Rezdiffra para adultos con MASH con cicatrización (fibrosis) en el hígado de moderada a avanzada sin cirrosis.
https://www.mayo.edu/research/clinical-trials/cls-20583455
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With...
Learn more about services at Mayo Clinic.
https://www.mayo.edu/research/clinical-trials/cls-20552883
A Phase 3 Study To Evaluate The Effect Of Resmetirom On Clinical Outcomes In Patients With...
Learn more about services at Mayo Clinic.